중증근무력증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 최종 용도별, 지역별, 경쟁별(2020-2030년)
Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End Use, Region and Competition, 2020-2030F
상품코드:1881591
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 중증근무력증 치료 시장은 2024년에 23억 2,000만 달러로 평가되었으며, 2030년까지 CAGR 7.44%로 성장하여 35억 7,000만 달러에 달할 것으로 예측됩니다.
중증근무력증 치료에는 신경과 근육의 전달 장애로 인한 다양한 정도의 골격근 약화 및 피로를 특징으로 하는 이 만성 자가면역성 신경근 질환을 관리하기 위한 약물 요법이 포함됩니다. 시장 성장의 주요 요인은 전 세계 발병률 증가와 조기 발견으로 이어지는 진단 능력의 향상입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
23억 2,000만 달러
시장 규모 : 2030년
35억 7,000만 달러
CAGR : 2025-2030년
7.44%
가장 빠르게 성장하는 부문
병원·진료소
최대 시장
북미
주요 시장 촉진요인
전 세계적으로 중증근무력증의 유병률이 증가함에 따라 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 전 세계적으로 진단되는 환자 수가 증가함에 따라 만성질환 관리가 필요한 환자층이 확대되고 있으며, 보다 폭넓은 치료 옵션과 기존 치료법에 대한 접근성 개선이 요구되고 있습니다.
주요 시장 과제
첨단 치료, 특히 생물학적 제제와 관련된 막대한 비용은 전 세계 중증근무력증 치료 시장의 성장에 큰 장벽으로 작용하고 있습니다. 이러한 고비용은 특히 의료 인프라가 미비한 지역이나 상환 정책이 까다로운 지역에서 환자의 접근과 치료 도입에 직접적인 제한을 가하고 있습니다.
주요 시장 동향
전 세계 중증근무력증 치료 시장은 맞춤형 의료 접근법의 확대에 따라 큰 영향을 받고 있습니다. 이러한 추세는 획일적인 전략에서 벗어나 치료 효과를 높이고 부작용을 최소화하기 위해 환자 개개인의 프로파일에 맞는 치료법을 제공하는 것을 중시하는 것입니다.
The Global Myasthenia Gravis Treatment Market, valued at USD 2.32 Billion in 2024, is projected to experience a CAGR of 7.44% to reach USD 3.57 Billion by 2030. Myasthenia Gravis treatment encompasses pharmaceutical interventions designed to manage this chronic autoimmune neuromuscular disorder, characterized by varying degrees of skeletal muscle weakness and fatigue resulting from impaired nerve-muscle communication. Market growth is primarily driven by the increasing prevalence of the condition globally and enhanced diagnostic capabilities that lead to earlier detection.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.32 Billion
Market Size 2030
USD 3.57 Billion
CAGR 2025-2030
7.44%
Fastest Growing Segment
Hospitals & Clinics
Largest Market
North America
Key Market Drivers
Rising global prevalence of Myasthenia Gravis significantly fuels the demand for effective treatments. The increasing number of diagnosed cases worldwide broadens the patient pool requiring chronic disease management, necessitating a wider array of therapeutic options and greater accessibility to existing ones. This trend is driven by improved diagnostic capabilities and enhanced disease awareness among healthcare professionals. For instance, according to a systematic review published in Neuroepidemiology, in October 2024, the mean prevalence rate of Myasthenia Gravis increased from 97.5 cases per million person-years during 1967-2007 to 220.1 cases per million person-years in the 2008-2022 timeframe.
Key Market Challenges
The substantial cost associated with advanced therapies, particularly biologics, presents a significant impediment to the growth of the Global Myasthenia Gravis Treatment Market. These high expenditures directly constrain patient access and adoption, especially in regions with developing healthcare infrastructure or stringent reimbursement policies. Healthcare systems and individual patients often struggle to absorb the ongoing financial burden of these advanced treatments, leading to delays in initiation or discontinuation of therapy.
Key Market Trends
The global Myasthenia Gravis treatment market is significantly influenced by the expansion of personalized medicine approaches. This trend emphasizes tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all strategy to improve efficacy and minimize adverse effects. The increasing understanding of disease heterogeneity and the identification of specific biomarkers are crucial to this evolution. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) 2024 Special 301 Submission, PhRMA member companies invested nearly $101 billion in research and development (R&D) in 2022 alone, underscoring the extensive financial commitment towards innovative and personalized therapeutic solutions.
Key Market Players
Alexion Pharmaceutical Inc.
Grifols International, S.A.
Avadel Pharmaceuticals, Plc.
Novartis AG
Pfizer, Inc.
AbbVie Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc.
Bausch Health Companies Inc.
Report Scope:
In this report, the Global Myasthenia Gravis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Myasthenia Gravis Treatment Market, By Treatment Type:
CholinesteraseInhibitors
Chronic Immunomodulators
Monoclonal Antibodies
Rapid Immunotherapies
Thymectomy
Others
Myasthenia Gravis Treatment Market, By End use:
Hospitals & Clinics
Ambulatory Surgical Centers
Others
Myasthenia Gravis Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Myasthenia Gravis Treatment Market.
Available Customizations:
Global Myasthenia Gravis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Myasthenia Gravis Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (CholinesteraseInhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
5.2.2. By End use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Myasthenia Gravis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By End use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Myasthenia Gravis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By End use
6.3.2. Canada Myasthenia Gravis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By End use
6.3.3. Mexico Myasthenia Gravis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By End use
7. Europe Myasthenia Gravis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By End use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Myasthenia Gravis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By End use
7.3.2. France Myasthenia Gravis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By End use
7.3.3. United Kingdom Myasthenia Gravis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By End use
7.3.4. Italy Myasthenia Gravis Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By End use
7.3.5. Spain Myasthenia Gravis Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By End use
8. Asia Pacific Myasthenia Gravis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By End use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Myasthenia Gravis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By End use
8.3.2. India Myasthenia Gravis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By End use
8.3.3. Japan Myasthenia Gravis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By End use
8.3.4. South Korea Myasthenia Gravis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By End use
8.3.5. Australia Myasthenia Gravis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By End use
9. Middle East & Africa Myasthenia Gravis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By End use
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Myasthenia Gravis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By End use
9.3.2. UAE Myasthenia Gravis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By End use
9.3.3. South Africa Myasthenia Gravis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By End use
10. South America Myasthenia Gravis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By End use
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Myasthenia Gravis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By End use
10.3.2. Colombia Myasthenia Gravis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By End use
10.3.3. Argentina Myasthenia Gravis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By End use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Myasthenia Gravis Treatment Market: SWOT Analysis
